Business Context and Reporting Period
This Form 8-K Current Report was filed by BioNexus Gene Lab Corp. (BGLC) on November 6, 2023. The Company is incorporated in Wyoming and its common stock trades on the Nasdaq Capital Market. The report addresses a regulatory notice received from the Nasdaq Stock Market regarding compliance with continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the Company's stock price performance relative to Nasdaq listing rules.
Material Changes
The primary material event is the Company's failure to maintain the minimum bid price requirement of $1.00 per share under Nasdaq Continued Listing Rule 5550(a)(2). Specifically, the closing bid price remained below $1.00 for 33 consecutive business days, spanning from September 20, 2023, through November 3, 2023.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-day compliance period ending May 6, 2024, to regain compliance.
- Regaining Compliance: To cure the deficiency, the closing bid price must reach at least $1.00 for a minimum of ten consecutive business days within the compliance period.
- Secondary Compliance: If the initial period is unsuccessful, the Company may apply for an additional 180-day period, provided it meets other initial listing standards (excluding the bid price) and demonstrates the ability to cure the deficiency.
- Delisting Risk: There is no assurance that the Company will regain compliance. Failure to do so may result in delisting by Nasdaq.
- Current Status: The notice has no immediate impact on trading; the stock remains listed and traded on the Nasdaq Capital Market pending compliance.
Investor Verification Checklist
- Verify the current closing bid price of BGLC stock to assess proximity to the $1.00 threshold.
- Monitor the Company's progress toward achieving ten consecutive days of trading at or above $1.00 before the May 6, 2024 deadline.
- Review future filings for any announcements regarding a reverse stock split or other corporate actions intended to address the bid price deficiency.
- Check for any additional Nasdaq correspondence regarding the Company's eligibility for a second compliance period if the first is missed.